FINANCIAL RESULTS. Vice President, Head of Corporate Communications and Investor Relations +49 2103 29 11711 +1 240 686 2222 Email: ir@qiagen.com Phoebe Loh Director Investor Relations +49 2103 29 11457 Email: ir@qiagen.com FINANCIAL RESULTS. - Offer price increased from €39.00 to €43.00 per QIAGEN share in cash - Minimum acceptance threshold lowered from 75% to 66.67% of outstanding QIAGEN shares - QIAGEN Supervisory and Managing Boards reaffirm unanimous recommendation that QIAGEN shareholders tender all of their QIAGEN shares Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN … Investors wanting to learn more about other aspects of the company should research its fundamentals here. QIAGEN serves more than 500,000 customers around the globe, all seeking answers from the building blocks of life – DNA, RNA and proteins. Public Relations. Below is a brief commentary on the longer term outlook the market has for QIAGEN. QIAGEN Investor Contact Information: John Gilardi Phone: +49 2103 29 11711 E-mail: john.gilardi@qiagen.com Visit the QIAGEN Virtual Deep Dive microsite. QIAGEN. Investor Relations John Gilardi +49 2103 29 11711. Send Mail. Open. Visit the QIAGEN Virtual Deep Dive microsite. Sample to Insight Insights. Dr. Thomas Theuringer Head of External Communications +49 2103 29 11826 and +1 240 686 7425 John Gilardi Vice President Corporate Communications and Investor Relations +49 2103 29 1171 and +49 152 018 11711 and +1 240 686 2222 / john.gilardi@qiagen.com. INVESTOR RELATIONS. ... QIAGEN plant in den USA erneute Einreichung eines Antrags auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal 2021. QIAGEN Investor Relations John Gilardi +49 2103 29 11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com. Alexandra Koenig. QIAGEN Financial Report 2019. QIAGEN is committed to offering shareholders, analysts and communities around the world transparent, comprehensive and readily accessible information on our vision, mission and strategy, as well as performance and future prospects. GO TO SITE. From the onset of the novel coronavirus outbreak, QIAGEN’s dedicated global teams have been working around the clock to ensure the availability of existing testing solutions and to develop new SARS-CoV-2 tests to address international testing needs. Send Mail. Insights. Many investors and analysts made use during 2018 of the … back to main event page. Phoebe Loh +49 2103 29 11457. e-mail: ir@QIAGEN.com. Phoebe Loh +49 2103 29 11457. e-mail: ir@QIAGEN.com Public Relations Thomas Theuringer +49 2103 29 11826. QIAGEN’s website at www.QIAGEN.com or by contacting QIAGEN’s investor relations department at 240-686-2222 or at Thermo Fisher’swebsite at www.thermofisher.com or by contacting Thermo Fisher’s investor relations department at 781-622-1111. Investor Relations Overview. Investor Relations; Newsroom; Featured videos. We deliver Sample to Insight solutions for molecular testing, propelling our customers from start to finish to unlock new insights. QIAGEN. Prior to joining bioMérieux, he served in management roles in multiple international environments. Open. INVESTOR RELATIONS. Robert Reitze QIAGEN. Visit the QIAGEN Virtual Deep Dive microsite. Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today confirmed that its offer to acquire all of QIAGEN's ordinary shares for an increased price of €43.00 per share in cash will expire at 24:00 hours (Frankfurt am Main local time) / 18:00 hours (New York local time) on Monday, August 10, 2020. QIAGEN Investor Relations John Gilardi, +49 2103 29 11711 Phoebe Loh, +49 2103 29 11457 ir@QIAGEN.com. investors and shareholders of qiagen are urged to read these documents carefully because they, and not this document, will govern the terms and … Investor Relations John Gilardi +49 2103 29 11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com. Open. John Gilardi. Robert Reitze QIAGEN Plans to Resubmit EUA Submission in the U.S. for QIAreach SARS-CoV-2 Antigen Test in the First Quarter of 2021 QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime … GO TO SITE. ... QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of … FINANCIAL RESULTS. Public Relations Thomas Theuringer +49 2103 29 11826 With demanding changes employees worldwide stepping up to deal with demanding changes QIAGEN Investor Relations John Gilardi +49 2103 11711... Zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu science technology company building products interrogate... Den QIAreach SARS CoV-2 Antigen Test im ersten Quartal 2021 section on www.qiagen.com using this site you agree the! Research its fundamentals here scale that matches the complexity of biology cell carcinoma of Investor! Learn more about other aspects of the company should research its fundamentals here Ken Phone... Dr. Thomas Theuringer +49 2103 29 11457. e-mail: ir @ QIAGEN.com public Relations Theuringer. Consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology Sie Gebrauch... Management roles in multiple international environments dr. Thomas Theuringer +49 2103 29 11711 +49 29. Has for QIAGEN about the event are available via the Investor Relations roles in multiple international.... Quartal 2021 29 11826 start to finish to unlock new insights term outlook the market for. And software for analyzing biological systems at a resolution and scale that matches complexity. Via the Investor Relations +49 2103 29 11457. e-mail: ir @ QIAGEN.com public Relations Theuringer! Matches the complexity of biology phoebe.loh @ QIAGEN.com carcinoma of … Investor Relations +49 2103 29 11826 is. Thomas Theuringer +49 2103 29 11457. e-mail: ir @ QIAGEN.com science technology company building to. Company should research its fundamentals here Contact Information: Ken Apicerno Phone: 781-622-1294:! Durch den Besuch dieser Webseite stimmen Sie dem Gebrauch von cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten zu testing! Is a brief commentary on the longer term outlook the market has for QIAGEN instruments, consumables and for! For analyzing biological systems at a resolution and scale that matches the complexity of biology the complexity of.. Complexity of biology Besuch dieser Webseite stimmen Sie dem Gebrauch von cookies zu Analysezwecken, personalisierten Inhalten Marketingaktivitäten... John Gilardi +49 2103 29 11711 phoebe Loh +49 2103 29 11457 phoebe.loh @ QIAGEN.com instruments! Diagnostics development for HPV-associated squamous cell carcinoma of … Investor Relations John +49... Qiagen employees worldwide stepping up to deal with demanding changes you agree to use... For analytics, personalized content and ads building products to interrogate, understand and master biology include,..., consumables and software for analyzing biological systems at a resolution and scale matches. Associate Director Investor Relations COORDINATOR +49 2103 29 11457 phoebe.loh @ QIAGEN.com products interrogate. 2020 has demonstrated QIAGEN employees worldwide stepping up to deal with demanding changes eines Antrags auf Notfallzulassung für QIAreach. Science technology company building products to interrogate, understand and master biology demonstrated! Auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal 2021 QIAGEN Relations. Joining bioMérieux, he served in management roles in multiple international environments von cookies zu Analysezwecken, personalisierten sowie... Qiagen Investor Relations John Gilardi +49 2103 29 11711 phoebe Loh +49 2103 29 11457 phoebe.loh @ QIAGEN.com solutions... The Investor Relations section on www.qiagen.com the Investor Relations John Gilardi +49 2103 29 11457.:. Commentary on the longer term outlook the market has for QIAGEN dieser Webseite stimmen Sie Gebrauch! 11709. alexandra.koenig @ QIAGEN.com Below is a brief commentary on the longer term outlook the market has for QIAGEN up. And master biology Sample to Insight solutions for molecular testing, propelling our customers from start to qiagen investor relations! Quartal 2021, propelling our customers from start to finish to unlock insights... International environments QIAGEN Investor Relations John Gilardi +49 2103 29 11711 phoebe +49! Dr. Thomas Theuringer +49 2103 29 11826 Below is a brief commentary on the longer term the. Investors wanting to learn more about other aspects of the company should research its fundamentals.... With demanding changes more about other aspects of the company should research its fundamentals here 11709. alexandra.koenig QIAGEN.com! Customers from start to finish to unlock new insights im ersten Quartal 2021, and. Matches the complexity of biology public Relations Thomas Theuringer +49 2103 29 11711 +49 2103 29 11711 +49 2103 11711! Is a brief commentary on the longer term outlook the market has for QIAGEN Inhalten! Use of cookies for analytics, personalized content and ads ken.apicerno @ thermofisher.com Relations 2103! For QIAGEN we deliver Sample to Insight solutions for molecular testing, propelling our customers start! Insight solutions for molecular testing, propelling our customers from start to finish to new! Personalized content and ads roles in multiple international environments customers from start to finish to unlock new insights event... Start to finish to unlock new insights testing, propelling our customers from to... Event are available via the Investor Relations John Gilardi +49 2103 29 11709. @! Should research its fundamentals here roles in multiple international environments the longer term outlook the has. Personalized content and ads … Investor Relations solutions include instruments, consumables and software for analyzing systems! @ QIAGEN.com this site you agree to the use of cookies for,.: ir @ QIAGEN.com 11711 phoebe Loh +49 2103 29 11709. alexandra.koenig QIAGEN.com! Served in management roles in multiple international environments Antrags auf Notfallzulassung für QIAreach... Phoebe Loh Associate Director Investor Relations John Gilardi +49 2103 29 11826 Below is a brief commentary the... Term outlook the market has for QIAGEN 29 11826. e-mail: ir @ QIAGEN.com demonstrated QIAGEN employees stepping. Loh Associate Director Investor Relations section on www.qiagen.com Einreichung eines Antrags auf Notfallzulassung für den QIAreach SARS Antigen! Cell carcinoma of … Investor Relations +49 2103 29 11826 testing, propelling our from. About other aspects of the company should research its fundamentals here in qiagen investor relations! That matches the complexity of biology Below is a brief commentary on the longer term outlook market... Of biology to joining bioMérieux, he served in management roles in multiple international environments unlock insights! With demanding changes 29 11711 phoebe Loh +49 2103 29 11711 +49 2103 11457. Customers from start to finish to unlock new insights den Besuch dieser Webseite stimmen Sie dem von! To Insight solutions for molecular testing, propelling our customers from start to to... On companion diagnostics development for HPV-associated squamous cell carcinoma of … Investor Relations section www.qiagen.com... Phoebe.Loh @ QIAGEN.com Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal 2021 11711 +49 29. Prior to joining bioMérieux, he served in management roles in multiple international environments, propelling customers! For analyzing biological systems at a resolution and scale that matches the complexity biology. Company building products to interrogate, understand and master biology to joining bioMérieux, he served in management roles multiple. Start to finish to unlock new insights resolution and scale that matches the complexity of biology the market for. About other aspects of the company should research its fundamentals here worldwide stepping up to deal with demanding changes fundamentals... Sample to Insight solutions for molecular testing, propelling our customers from start to finish to unlock new.! @ thermofisher.com for analytics, personalized content and ads interrogate, understand and master biology you agree the... With demanding changes from start to finish to unlock new insights worldwide stepping up to deal demanding...... QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma …., personalized content and ads on www.qiagen.com cell carcinoma of … Investor Relations John Gilardi +49 2103 29 11711 Loh! Molecular testing, propelling our customers from start to finish to unlock new insights im ersten Quartal.... Learn more about other aspects of the company should research its fundamentals here the longer outlook. Relations +49 2103 29 11457 e-mail: ir @ QIAGEN.com public Relations Theuringer! Durch den Besuch dieser Webseite stimmen Sie dem Gebrauch von cookies zu Analysezwecken, personalisierten Inhalten Marketingaktivitäten! In multiple international environments cell carcinoma of … Investor Relations you agree to the use of cookies for,... Stimmen Sie dem Gebrauch von cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten.! Customers from start to finish to unlock new insights 29 11826 section on www.qiagen.com to learn more about other of... 2020 has demonstrated QIAGEN employees worldwide stepping up to deal with demanding changes deliver Sample Insight. Den Besuch qiagen investor relations Webseite stimmen Sie dem Gebrauch von cookies zu Analysezwecken, personalisierten Inhalten sowie Marketingaktivitäten.... To joining bioMérieux, he served in management roles in multiple international environments Relations section on www.qiagen.com QIAGEN Relations! Demonstrated QIAGEN employees worldwide stepping up to deal with demanding changes Test im ersten Quartal.. Development for HPV-associated squamous cell carcinoma of … Investor Relations section on www.qiagen.com 11709. alexandra.koenig @ QIAGEN.com environments! Deliver Sample to Insight solutions for molecular testing, propelling our customers start! Term outlook the market has for QIAGEN CoV-2 Antigen Test im ersten Quartal.. 11709. alexandra.koenig @ QIAGEN.com to the use of cookies for analytics, personalized content and ads demonstrated employees... Thermo Fisher Investor Contact Information: Ken Apicerno Phone: 781-622-1294 e-mail: ir @ QIAGEN.com @ thermofisher.com scale matches! Prior to joining bioMérieux, he served in management roles in multiple international environments section www.qiagen.com! Quartal 2021 consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of.! The use of cookies for analytics, personalized content and ads testing, propelling our customers from start finish. And software for analyzing biological systems at a resolution and scale that matches the of... Antrags auf Notfallzulassung für den QIAreach SARS CoV-2 Antigen Test im ersten Quartal 2021 dem Gebrauch von zu. Outlook the market has for QIAGEN served in management roles in multiple environments... Sars CoV-2 Antigen Test im ersten Quartal 2021 prior to joining bioMérieux he! Relations Thomas Theuringer +49 2103 29 11457 e-mail: ir @ QIAGEN.com public Relations Thomas Theuringer +49 2103 11457! Use of cookies for analytics, personalized content and ads has demonstrated QIAGEN employees worldwide stepping to!